CANCER: More profitable than addiction? –

April 20, 2019 – The top value stock among cancer drug developers

Sean Williams (Exelixis): Although big pharma is often viewed as the smartest way for investors to take advantage of novel cancer treatments, my preference among cancer stocks has been the same for years: midcap biotech Exelixis.

Admittedly, Exelixis isn’t particularly diversified, which is usually a red flag for pharma and biotech investors. But Exelixis’ bread-and-butter drug has delivered multiple label expansions, has additional indication opportunities, and has made Exelixis one of the cheapest growth stocks you can buy in the entire healthcare sector.

Exelixis’ Cabometyx was first approved in April 2016, following positive data from the Meteor trial, as a second-line treatment for patients with advanced renal cell carcinoma (RCC). It was the first therapy to deliver a “trifecta” in treating advanced RCC patients. In other words, it provided a statistically significant improvement in objective response rate, progression-free survival, and median overall survival.

Full Story @ Fool.com